关注
Hendrik-Tobias Arkenau
Hendrik-Tobias Arkenau
Ellipses Pharma
在 ellipses.life 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
12772019
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ...
The Lancet 379 (9829), 1893-1901, 2012
10132012
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study
T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ...
JAMA oncology 3 (9), e172411-e172411, 2017
9082017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
LY Dirix, I Takacs, G Jerusalem, P Nikolinakos, HT Arkenau, ...
Breast cancer research and treatment 167, 671-686, 2018
7092018
Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE …
MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ...
JAMA oncology 5 (4), 546-550, 2019
4462019
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, ...
The Lancet Oncology 19 (11), 1437-1448, 2018
4432018
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
4242020
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO …
R Porschen, HT Arkenau, S Kubicka, R Greil, T Seufferlein, W Freier, ...
Journal of Clinical Oncology 25 (27), 4217-4223, 2007
3642007
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and …
J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ...
Journal of Clinical Oncology 39 (4), 273-284, 2021
3532021
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
R Kefford, H Arkenau, MP Brown, M Millward, JR Infante, GV Long, ...
Journal of Clinical Oncology 28 (15_suppl), 8503-8503, 2010
3532010
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, HT Arkenau, JE Ang, I Ledaki, G Attard, CP Carden, AHM Reid, ...
Annals of oncology 20 (1), 27-33, 2009
2822009
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a …
RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ...
The Lancet Oncology 20 (8), 1109-1123, 2019
2452019
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials
HT Arkenau, D Arnold, J Cassidy, E Diaz-Rubio, JY Douillard, H Hochster, ...
Journal of Clinical Oncology 26 (36), 5910-5917, 2008
2292008
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
S Pacey, RH Wilson, M Walton, MM Eatock, A Hardcastle, A Zetterlund, ...
Clinical cancer research 17 (6), 1561-1570, 2011
2272011
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials
HT Arkenau, J Barriuso, D Olmos, JE Ang, J de Bono, I Judson, S Kaye
Journal of clinical oncology 27 (16), 2692-2696, 2009
2092009
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
KL Nathanson, AM Martin, B Wubbenhorst, J Greshock, R Letrero, ...
Clinical cancer research 19 (17), 4868-4878, 2013
1942013
Targeting BRAF for patients with melanoma
HT Arkenau, R Kefford, GV Long
British journal of cancer 104 (3), 392-398, 2011
1942011
Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer
TK Choueiri, E Plimack, HT Arkenau, E Jonasch, DYC Heng, T Powles, ...
Journal of Clinical Oncology 35 (26), 2993-3001, 2017
1812017
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
HT Arkenau, D Olmos, JE Ang, J De Bono, I Judson, S Kaye
British journal of cancer 98 (6), 1029-1033, 2008
1762008
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
B Sirohi, D Cunningham, R Powles, F Murphy, T Arkenau, A Norman, ...
Annals of Oncology 19 (7), 1312-1319, 2008
1752008
系统目前无法执行此操作,请稍后再试。
文章 1–20